Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yuri Teranishi-Ikawa"'
Autor:
Hikaru Koga, Takashi Yamano, Juan Betancur, Satoko Nagatomo, Yousuke Ikeda, Kazuki Yamaguchi, Yoshiaki Nabuchi, Kazuki Sato, Yuri Teranishi-Ikawa, Motohiko Sato, Hiroyuki Hirayama, Akira Hayasaka, Takuya Torizawa, Kenta Haraya, Zenjiro Sampei, Hirotake Shiraiwa, Takehisa Kitazawa, Tomoyuki Igawa, Taichi Kuramochi
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTEfficient production of bispecific antibodies (BsAbs) in single mammalian cells is essential for basic research and industrial manufacturing. However, preventing unwanted pairing of heavy chains (HCs) and light chains (LCs) is a challenging t
Externí odkaz:
https://doaj.org/article/281415e66ed346d99393535f365215ff
Autor:
Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki, Shun-Ichiro Komatsu, Atsushi Muto, Kei Nishimura, Momoko Okuda, Hisakazu Sanada, Motohiko Sato, Norihito Shibahara, Tetsuya Wakabayashi, Koji Yamaguchi, Akiko Matsusaki, Zenjiro Sampei, Hirotake Shiraiwa, Hiroko Konishi, Yoshiki Kawabe, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa
Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e05c434bee4d4affb01dcc8f26f39e
https://doi.org/10.1101/2022.12.19.520692
https://doi.org/10.1101/2022.12.19.520692
